Kornimate/medical-research-clean huggingface dataset:
fluids administration during combined clonidine-arginine growth hormone stimulation test

Conditions: Growth Hormone Deficiency

Summary: the diagnosis of growth hormone deficiency in childhood requires the performance of an artificial pharmacological stimulation tests. there are number of substances that increase the secretion of growth hormone, among them clonidine and arginine. one of the possible side effects of both clonidine and arginine is a reduction in the blood pressure due to a decreased heart output and declined contraction of peripheral blood vessels. in cases where values of blood pressure at the end of the test are not recovered after two sessions of 15 minutes of physical activity, the patient is treated with i. v of 9%normal saline (0. 20cc /kg) administrated over 30-60 minutes. the aim of the proposed study is to test whether administration of fluids during the combined growth hormone stimulation test clonidine-arginine will help in the recovery process from the test (blood pressure \> 90/50 mmhg after performing physical activity defined as 15-minutes hike in two consecutive sessions). the study design will be randomized, controlled, 2 arms study.


Eligibility criteria:
inclusion criteria: * children referred to combined arginine- conidine growth hormone stimulation test * girls: 7-14 years old and boys: 7-16 years old * weight\>20 kg * normal thyroid function exclusion criteria: * bmi over percentile 85 * genetic syndromes or chromosomal disorders * steroid treatment * renal failure * heart failure

Keywords: growth hormone stimulation tests
vasculitis pregnancy registry

Conditions: Vasculitis; Behcet's Disease; CNS Vasculitis; Cryoglobulinemic Vasculitis; Eosinophilic Granulomatosis With Polyangiitis (EGPA); Churg-Strauss Syndrome (CSS); Granulomatosis With Polyangiitis (GPA); Wegener's Granulomatosis; IgA Vasculitis; Henoch-Schoenlein Purpura (HSP); Microscopic Polyangiitis (MPA); Polyarteritis Nodosa (PAN); Takayasu Arteritis (TAK); Urticarial Vasculitis; Systemic Vasculitis

Summary: the purpose of this study is to learn about the experience of women with vasculitis who become pregnant. in particular, the study will consist of several online surveys to assess 1. each woman's vasculitis severity and pregnancy-related experiences, and 2. pregnancy outcomes.

the study will consist of several on-line surveys to assess each woman's vasculitis severity, pregnancy-related experiences, and pregnancy outcomes. participants will be asked to complete questionnaires at study entry, during the second trimester, during the third trimester, and postpartum. investigators estimate that it will take approximately 20 minutes to complete each survey. the survey is available in spanish, portuguese, italian, and turkish. all women enrolled in the vasculitis patient-powered research network (vpprn) (with specified disease, sex, and age inclusion criteria described below) will be invited via email to participate in this on-line study. the survey data will be stored by the data management and coordinating center (dmcc) at the university of south florida. upon conclusion of the study period, the data will be sent to the study chairs.

Eligibility criteria:
inclusion criteria: 1. women 18 years of age or older with one of the following diseases may take part in the study: * behçet's disease; * central nervous system (cns) vasculitis; * cryoglobulinemic vasculitis (cryoglobulinemia); * eosinophilic granulomatosis with polyangiitis (also called churg-strauss syndrome); * giant cell (temporal) arteritis (gca); * granulomatosis with polyangiitis (also called wegener's); * iga vasculitis (henoch-schoenlein purpura); * microscopic polyangiitis (mpa); * polyarteritis nodosa (pan); * takayasu's arteritis (tak); * urticarial vasculitis; * other/suspected diagnosis. 2. women must be pregnant (self-report) at the time of enrollment into the registry. exclusion criteria: 1. non-english speaking, with the exception of people who speak spanish, portuguese, italian, or turkish. 2. unable to provide consent.
study of shunt flow sensor accuracy in extra-ventricular drains.

Conditions: Hydrocephalus; Nervous System Diseases; Infant, Newborn Diseases

Summary: the study hypothesis is that an ultrasonic flow sensor can accurately measure flow in hydrocephalic shunts. the ultrasonic sensor will measure cerebrospinal fluid drainage in hydrocephalus patients with external ventriculostomies and extra-ventricular drainage systems. the sensor measurements will be compared with the volume of fluid collected by the drainage bag. after a 24-hour measurement period, the doctor will change the drainage bag position to simulate the patient sitting up and leaning back, to see if this temporarily stops flow through the drainage line. this data will show whether the sensor accurately measures typical drainage flows seen in hydrocephalus patients. this research will help develop an implantable flow monitor for pediatric hydrocephalus patients.


Eligibility criteria:
inclusion criteria: * diagnosed with hydrocephalus * instrumented with an extraventricular drainage system exclusion criteria: * not diagnosed with hydrocephalus * not instrumented with an extraventricular drainage system

Keywords: hydrocephalus shunt dysfunction shunt flow
impact of intermittent kangaroo mother care versus conventional care method on vital sign and arterial oxygen saturation in preterm hospitalized in neonatal intensive care unit

Conditions: Kangaroo Mother Care Method

Summary: - to study the vital sign ,oxygen arterial saturation of preterm babies provided skin to skin contact versus conventional care from birth to discharge

the mother and baby will be supported by a nurse and researcher. hence, the study group mothers will be trained properly, and the required information and explanations along with displaying the video description about the kmc method will be provided for them, and the kmc will apply to their newborns. thus, the naked newborn, only wearing diaper and cap, was placed in a straight state between the mother's breasts and supported by a cloth bag. the caring is performed for 3 consecutive days, three times a day and each time for 2-h. the procedure will be conducted for all samples by the head nurse and with the researcher's presence and monitoring in the morning shift, and the mothers should be supported and encouraged during the caring process. the changes in pulse ,respiration, temperature, and arterial oxygen saturation rate of the study group is controlled and recorded during the care process, at 60 min after starting the procedure and at the end of caring process before returning the newborn to the incubator. the mentioned items in the control group (conventional incubator care) should also measure and recorded simultaneously with the study group. the pulse oximetry in nicu used to measure the arterial oxygen saturation rate, and a mercury thermometer was used to measure the temperature with an auxiliary approach for 3 min. to maintain the reliability of the instrument during the research, the same pulse oximetry device and monitoring system will be applied to newborns in the same situation. the pulse oximetry probe will be taped to the toe of the left foot of all newborns

Eligibility criteria:
inclusion criteria: birth weight between 1200 to 1800 gram gestational age 28 weeks to 36+6 weeks clinically stable off oxygen support hemodynamically stable baby no surgery performed on baby no cardiac ,nervous system problems - exclusion criteria: extreme preterm\ 37 weeks -

Keywords: vital signs intensive care
liraglutide and a calorie restricted diet augments weight loss and decreases risk of type 2 diabetes and cvd.

Conditions: Pre-diabetes; Older Adults

Summary: the goal of this study is to evaluate the hypothesis that the addition of liraglutide, a long-acting glucagon-like peptide 1 (glp-1) analogue, to a calorie-restricted diet will lead to greater weight loss than will a calorie-restricted diet alone in subjects who are older (50 to 60 years of age), overweight/obese, and prediabetic. these individuals have been selected for study because they are at greatly increased risk to develop type 2 diabetes (2dm) and cardiovascular disease (cvd), and it is hypothesized that the addition of liraglutide to a calorie-restricted diet will significantly decrease risk of these adverse outcomes. there is considerable evidence that glp-i compounds, including liraglutide, improve glycemic control in patients with manifest 2dm. however, there is relatively little information as to the potential utility of these compounds in nondiabetic individual at greatly increased risk of 2dm and cvd. this research proposal is aimed at providing some of this information by quantifying the effects of liraglutide, a long-acting glp-1 analogue, on weight loss, insulin secretion, insulin action, and multiple cvd risk factors in a very high risk group-older, overweight/obese, prediabetic individuals. furthermore, by using specific methods, not surrogate estimates, and avoiding the confounding effects of glucotoxicity, it will be possible to gain new insights into the effects of glp-1 on insulin secretion and insulin action.


Eligibility criteria:
inclusion criteria: ifg, or igt bmi 27.0-37.0 kg/m2 exclusion criteria: dm, cad, severe anemia, kidney or liver disease, hx of pancreatitis, gallstones, etoh abuse, personnel or family history of medullary thyroid carcinoma or men-2
hypertension in hemodialysis

Conditions: Hypertension; Left Ventricular Hypertrophy

Summary: how high blood pressure in hemodialysis patients should be diagnosed and treated using medications or without medications is the purpose of this study.


Eligibility criteria:
- adults with hypertension on hemodialysis hypertensive, long-term (3 months or more) hemodialysis patients will be studied over a 6 hemodialysis baseline phase during which 44-hour interdialytic ambulatory bp will be performed and baseline symptoms collected. patients with well-controlled hypertension, on anti-hypertensive therapy will have blood pressure medications withdrawn until they become hypertensive as assessed by 44-hour interdialytic ambulatory blood pressure recording. we will exclude patients who have had vascular event (stroke, myocardial infarction or limb ischemia requiring bypass) within previous six months, ambulatory bp \>170 mm hg systolic or \>100 mm hg diastolic, those who miss 2 or more hemodialysis treatments in the previous month, abuse street-drugs, require home oxygen, have symptomatic congestive heart failure or are morbidly obese (body mass index \> 40 kg/m2).

Keywords: hemodialysis
extraocular muscle stretching as a weakening procedure

Conditions: Strabismus, Comitant

Summary: interventional case series. non-operated patients with an indication of medial rectus muscle weakening surgery (deviation up to 20 pd) who could cooperate with topical or sub-tenon's anesthesia. clinical workup includes routine complete ophthalmological evaluation. one double needle 6/0 mersilene suture is used on each side of the muscle at 4 mm distance of the insertion and pulled / stretched to insert in the sclera 3-5 mm posterior to the muscle locking passes. seven patients with esotropia of 12-20 pd were included.


Eligibility criteria:
inclusion criteria: * patients requiring weakening of medial rectus muscle(s) for 12-20 pd of esotropia who could cooperate with topical / sub-tenon's anesthesia, and had no previous eye muscle surgery exclusion criteria: * patients with previous strabismus surgery
a study to evaluate safety and immunogenicity of sequential vaccination of sabin inactivated poliomyelitis vaccine (vero cell) and live attenuated poliomyelitis vaccine in healthy 2-month-old infants

Conditions: Poliomyelitis

Summary: the goal of this clinical trial is to evaluate the immunogenicity and safety of a sabin inactivated poliomyelitis vaccine (sipv) and a commercially available live attenuated poliomyelitis vaccine (bopv) according to the "2+1 sequential" immunization program (sipv-sipv-bopv) in 2-month-old healthy infants.

a total of approximately 300 infants 2 months of age (over 60 days old and less than 90 days old) will be enrolled and randomized in 1:1 ratio into the study group and control group, with 150 participants in each group.the study group will receive study sipv developed by biominhai and control group will receive wipv developed by sanofi pasteur s.a. the "2+1 sequential" procedure consists of 2 doses of inactivated vaccine (sipv or wipv) and 1 dose of bopv, a total of 3 doses, with 1 month between each vaccination. this study has indicated that the sipv is not inferior to the wipv in terms of immunogenicity and safety according to the "2+1 sequential" immunization program in 2-month-old healthy infants.

Eligibility criteria:
inclusion criteria: 1. healthy permanent residents aged 2 months (over 60 days and less than 90 days); 2. infant's legal guardians agree to sign the informed consent forms voluntarily; 3. infant's legal guardians are able to comply with the requirements of the clinical trial protocol; 4. armpit temperature ≤ 37.0 ℃ exclusion criteria: 1. preterm birth (delivery before the 37th week of pregnancy). 2. previous vaccination against polio. 3. congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc. 4. history of polio. 5. history or family history of convulsions, seizures, encephalopathy, and neurological disorder. 6. history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the investigational vaccine. 7. individuals with immunodeficiency or receiving immunosuppression therapy. 8. disturbance of coagulation diagnosed by doctor (e.g., coagulation factors deficiency, coagulation disease, platelet abnormality) or obvious bruising or coagulation disorder. 9. known or suspected concomitant diseases include: respiratory disease, acute infection or active chronic disease, cardiovascular disease, liver and kidney disease, skin disease, mother with hiv infection. 10. administration of blood or blood-related products or immunoglobulins (hepatitis b immunoglobulins is acceptable). 11. history of administration of live attenuated vaccines within 14 days. 12. history of administration of subunit or inactivated vaccines within 7 days. 13. individuals with any acute diseases within 7 days, receiving antibiotics or antiviral therapy. 14. fever within 3 days (armpit temperature ≥38.0 ℃). 15. use of any investigational product recently, or have any conditions that the investigator believes may affect the evaluation of the trial.

Keywords: sipv bopv sequential immune
a clinical trial comparing efficacy and safety of sunitinib versus placebo for thetreatment of patients at high risk of recurrent renal cell cancer

Conditions: Kidney Neoplasms

Summary: to compare the disease free survival time and safety of sunitinib with placebo in adjuvant treatment patients at high risk of recurrent kidney cancer after surgery.


Eligibility criteria:
inclusion criteria: * high risk renal cancer per modified uiss criteria * eastern cooperative oncology group (ecog) 0-2 * predominant clear cell histology * no prior anti-cancer treatment * kidney tumor has been removed * no evidence of macroscopic disease following surgery exclusion criteria: * histologically undifferentiated carcinomas or collecting duct carcinoma, lymphoma, sarcoma or subjects with metastatic renal sites. * diagnosis of any second malignancy within the last 5 years, except basal cell carcinoma, squamous cell skin cancer, or in situ carcinoma of the cervix uteri that has been adequately treated with no evidence of recurrent disease for 12 months * known hiv or hepatitis * any severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration
31p-mrs and huntington disease

Conditions: Huntington Disease

Summary: the purpose of this study is to identify and quantify a brain energy deficit in huntington patients, using 31p-rmn spectroscopy.


Eligibility criteria:
inclusion criteria: * 5\<uhdrs\<50 * age\>18 years * ability to undergo mr scanning * covered by french social security exclusion criteria: * evidence of psychiatric disorder * attendant neurological disorder * contraindications to mri (claustrophobia, metallic or material implants) * severe head injury * unable to understand the protocol * pregnancy * failure to give informed consent * subjects with exclusion criteria required by french law (e.g. subjects who require a legally authorized representative to obtain consent) * unwillingness to be informed in case of abnormal mri

Keywords: energy metabolism spectroscopy
evaluation of the effect of output on new adhesives

Conditions: Ileostomy - Stoma

Summary: the study investigates the impanct real output has on the adhesion of a new adhesive


Eligibility criteria:
inclusion criteria: 1. have given written informed consent 2. be at least 18 years of age and have full legal capacity 3. have had a stoma for more than one year 4. have intact skin on the area used in the evalua-tion 5. has a stoma with a diameter up to (≤) 35 mm 6. have a peristomal area accessible for application of adhesive strips (assessed by investigating scientist) exclusion criteria: 1. currently receiving or have within the past 2 month received radio- and/or chemotherapy 2. currently receiving or have within the past month received topical steroid treatment in the peristomal skin area or systemic steroid (tablet/injection) treatment. 3. are pregnant or breastfeeding 4. having dermatological problems in the peristo-mal- or abdominal area (assessed by investigating scientist) 5. actively participating in other interventional clinical investigations or have previously participated in this investigation
a study to evaluate the safety, pharmacokinetics, and activity of gdc-6036 alone or in combination in participants with advanced or metastatic solid tumors with a kras g12c mutation

Conditions: Non-Small Cell Lung Cancer; Colorectal Cancer; Advanced Solid Tumors

Summary: this is a phase i dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (pk), and preliminary activity of gdc-6036 in patients with advanced or metastatic solid tumors with a kras g12c mutation.


Eligibility criteria:
inclusion criteria: * histologically documented advanced or metastatic solid tumor with kras g12c mutation. * women of childbearing potential must agree to remain abstinent or use contraception, and agree to refrain from donating eggs during the treatment period and after the final dose of study treatment as specified in the protocol. * men who are not surgically sterile must agree to remain abstinent or use a condom, and agreement to refrain from donating sperm during the treatment period and after the final dose of study treatment as specified in the protocol. exclusion criteria: * active brain metastases. * malabsorption or other condition that interferes with enteral absorption. * clinically significant cardiovascular dysfunction or liver disease.

Keywords: kras g12c non-small cell lung cancer colorectal cancer gdc-6036 metastatic solid tumor atezolizumab bevacizumab cetuximab erlotinib inavolisib gdc-1971 shp2
online health survey of patients with vitiligo vulgaris/ online survey of pediatric patients with vitiligo

Conditions: Vitiligo Vulgaris

Summary: the study is an on-line survey posted on survey monkey that addresses some demographic and environmental issues that could potentially relate to vitiligo vulgaris onset or disease exacerbation.

the survey is designed to look at some issues that are pertinent to individuals with vitiligo, including access to care, severity of disease, under-reported disease activity, causative and exacerbating factors and co-morbid illnesses.

Eligibility criteria:
inclusion criteria: * ability to complete survey exclusion criteria: * inability to complete survey

Keywords: vitiligo vulgaris autoimmunity thyroid disease
clinical outcome and cytokine expression after tka

Conditions: Osteoarthritis

Summary: comparison of coated and uncoated tka with regard to cytokine expression and clinical results

comparison of coated and uncoated tka with regard to cytokine expression and clinical results at 3 months, 1 year and 3 years after surgery

Eligibility criteria:
inclusion criteria: * primary and secondary osteoarthritis * understanding of german language exclusion criteria: * necessity of constrained tka * existence of other joint implants

Keywords: tka, cytokine, coating
a study to assess the effect of rho-kinase inhibitor ar-12286 ophthalmic solution 0.5% and 0.7% in patients with chronic angle-closure glaucoma

Conditions: Chronic Angle-closure Glaucoma

Summary: to evaluate the ocular hypotensive efficacy of rho kinase inhibitor (ar-12286 0.5% and 0.7%) ophthalmic solutions in patients diagnosed with chronic angle-closure glaucoma treated for 6 months. secondary outcome secondary objectives are: 1. to evaluate the early effect of rho kinase inhibitor (ar-12286) in reducing intraocular pressure (iop). 2. to evaluate the long term effect of the drug on iop. 3. to determine if ar-12286 can be used as directed therapy for cacg, reducing or eliminating the structural blockage of the trabecular meshwork that leads to development of elevated iop.


Eligibility criteria:
inclusion criteria: 1. patients between 50 and 85 years old; of either sex. 2. patients with cacg with ≥180⁰ pas 3. iop ≥22 mmhg prior to initiation of treatment in one or both eyes with two measurements taken two hours apart 4. no previous intraocular surgery except clear cornea phacoemulsification. 5. corrected visual acuity in both eyes ≥20/50 in the eligible eye 6. not more than 6 diopters spherical equivalent on the study eye 7. not more than 3 diopters cylinder equivalent on the study eye 8. have given written informed consent, prior to any investigational procedures. 9. ability to attend for the 6-month duration of the study exclusion criteria: 1. open angle glaucoma 2. closed angle glaucoma with \<180⁰ pas 3. intraocular pressure \>35 mmhg 4. severe glaucomatous damage 5. known hypersensitivity to any component of the formulation (benzalkonium chloride, etc.), or to topical anesthetics. 6. previous intraocular surgery except clear cornea phacoemulsification. 7. clinically significant ocular disease (e.g. corneal edema, uveitis, severe keratoconjunctivitis sicca) which might interfere with the study. 8. ocular medication of any kind within 30 days of base-line visit, with the exception of ocular hypotensive medications and/or drops for treatment of dry eye syndrome (which may be used throughout the study). 9. any abnormality preventing reliable applanation tonometry of either eye. 10. clinically significant systemic disease (e.g., uncontrolled diabetes, myasthenia gravis, hepatic, renal, endocrine or cardiovascular disorders) which might interfere with the study. 11. changes of systemic medication that could have a substantial effect on iop anticipated during the study. 12. participation in any investigational study within the past 30 days. 13. inability to perform reliable vf testing. 14. unwilling to sign the consent form approved by the institutional review board (irb) of the new york eye and ear infirmary. 15. self-reported poor compliance to treatment. 16. reluctance to return for scheduled follow-up visits. 17. patients not able to understand the nature of the study.